Merit Medical Systems stock hits 52-week low at $60.50

Merit Medical Systems hit a new 52-week low at $60.51, just above its $60.80 low, after falling 7.09% in the past week and 34.69% over the past year. The company also reported Q1 2026 EPS of $0.94, beating consensus by $0.11, and revenue of $382 million, about $4 million above expectations, while operating margin of 19.7% was 180 bps ahead of forecasts. Management slightly raised 2026 revenue guidance, but analysts remain mixed, with Needham at $90/Buy and BofA at $80/Neutral amid valuation and deal dilution concerns.

Analysis

MMSI looks like a classic “good company, bad tape” setup where the market is punishing the stock for near-term digestion rather than questioning the franchise. The key second-order issue is that a beat-and-raise that is only modestly constructive often fails to reset expectations when the prior ownership base is crowded with growth investors; that can extend multiple compression even if operations remain healthy. In that regime, the stock can keep working lower until estimate cuts stop, so the near-term risk is less about fundamentals breaking and more about sentiment and positioning staying bearish for another 1-2 quarters.

The more interesting tell is the gap between strong underlying profitability and downward analyst revisions. That usually signals the market is pricing in either slowing procedure growth, a tougher pricing environment, or dilution from capital allocation/M&A rather than an outright demand collapse. If so, the winners are likely larger med-tech peers with cleaner organic growth and less deal overhang, while suppliers tied to elective/procedural cadence can trade as a basket regardless of company-specific execution.

This is a setup where the stock can mean-revert quickly if management delivers one more clean quarter and guidance stops inching higher instead of resetting meaningfully. But absent an explicit catalyst, the base case is continued chop-to-lower over the next 4-8 weeks as analysts trim numbers and holders de-risk into any strength. The contrarian angle is that a quality screen may be underestimating how durable the cash generation is; if the market is over-penalizing dilution fears, the downside could be more limited than the chart implies once selling exhausts.

The most attractive risk/reward is probably not outright long stock immediately, but a staged entry after forced selling subsides or via options to define downside. A clean technical break below the recent low would likely trigger another leg of systematic selling, but a hold and reclaim of the 20-day range would suggest capitulation is ending.

Key Decisions for Investors

• Avoid chasing MMSI long immediately; wait 2-4 weeks for post-low stabilization or a reclaim of short-term moving averages before buying, since momentum sellers can still dominate and extend the drawdown another 5-10%.
• For a contrarian trade, buy MMSI call spreads 3-6 months out only after a confirmed base forms; target a 2:1 or better payoff if the stock re-rates toward prior trading range, with defined downside if analyst cuts continue.
• Pair trade: long higher-quality med-tech peers with stronger organic growth visibility versus short MMSI into earnings-season revisions; the relative-performance setup should work over 1-3 months if revisions keep drifting lower.
• If MMSI breaks decisively below the recent 52-week low, use that as a tactical short signal for a 2-6 week momentum trade, with a tight stop on any guidance-upgrade surprise or large insider/supportive corporate action.
• Watch for one more quarter of stable guidance and margin durability; if confirmed, add incrementally because the stock may be oversold relative to normalized cash flow and could rerate 15-20% from current levels.